A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
Launched by FUJIAN MATERNITY AND CHILD HEALTH HOSPITAL · Mar 7, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the relationship between the amount of human papillomavirus (HPV) in the body and the chances of high-grade squamous intraepithelial lesions (HSIL) coming back after treatment. HSIL is a type of cervical cell change that can lead to cervical cancer if not monitored closely. By understanding how the viral load (the amount of HPV present) affects HSIL recurrence, researchers hope to improve screening and treatment strategies for women with HPV infections.
To participate in this study, women aged 20 and older who have been diagnosed with HSIL in the last three months may be eligible. It's important that participants are not pregnant, have a sexual history, and have not taken certain medications or undergone specific treatments recently. Those who join the trial can expect to undergo testing that measures HPV viral load, which may help doctors better predict and manage their health in relation to HSIL. This study is currently recruiting participants, and your involvement could contribute to valuable findings in women's health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged 20 and over.
- • The result of cervical histopathology in the last 3 months was high-grade squamous intraepithelial lesion (HSIL).
- • Non pregnant people with sexual history.
- • Asexual life, no vaginal medication or flushing before 72 hours of sampling.
- Exclusion Criteria:
- • Within 8 weeks after pregnancy or postpartum.
- • Patients with history of genital tract tumor.
- • History of HPV vaccination.
- • Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
- • In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
- • Use antibiotics or vaginal microecological improvement products in recent 1 month.
About Fujian Maternity And Child Health Hospital
Fujian Maternity and Child Health Hospital is a leading healthcare institution in China, dedicated to providing comprehensive maternal and pediatric care. With a strong emphasis on research and innovation, the hospital actively engages in clinical trials aimed at enhancing healthcare outcomes for mothers and children. Leveraging a team of experienced healthcare professionals and state-of-the-art facilities, the hospital fosters a collaborative environment for clinical research, contributing to advancements in reproductive health and pediatric medicine. Its commitment to quality care and scientific inquiry positions Fujian Maternity and Child Health Hospital as a pivotal player in the field of maternal and child health research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Putian, Fujian, China
Longyan, Fujian, China
Zhangzhou, Fujian, China
Fuzhou, Fujian, China
Ningde, Fujian, China
Quanzhou, Fujian, China
Ningde, Fujian, China
Longyan, , China
Shenzhen, , China
Wuhan, , China
Xiamen, , China
Shenzhen, Guangdong, China
Patients applied
Trial Officials
Pengming Sun, PhD
Study Chair
Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials